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Background: We sought to identify high-risk areas of pancreatic cancer incidence, and determine if clusters of
persons diagnosed with pancreatic cancer were more likely to be located near arsenic-contaminated drinking water wells.
Methods: A total of 5,707 arsenic samples were collected from December 2000 to May 2008 by the Florida Department
of Health, representing more than 5,000 individual privately owned wells. During that period, 0.010 ppm (10 ppb) or
greater arsenic levels in private well water were considered as the threshold based on standard of United States
Environmental Protection Agency (EPA). Spatial modeling was applied to pancreatic cancer cases diagnosed between
1998–2002 in Florida (n = 11,405). Multivariable logistic regression was used to determine if sociodemographic indicators,
smoking history, and proximity to arsenic-contaminated well sites were associated with residence at the time of
pancreatic cancer diagnosis occurring within versus outside a cluster.
Results: Spatial modeling identified 16 clusters in which 22.6% of all pancreatic cancer cases were located. Cases living
within 1 mile of known arsenic-contaminated wells were significantly more likely to be diagnosed within a cluster of
pancreatic cancers relative to cases living more than 3 miles from known sites (odds ratio = 2.1 [95% CI = 1.9, 2.4]).
Conclusions: Exposure to arsenic-contaminated drinking water wells may be associated with an increased risk of
pancreatic cancer. However, case–control studies are needed in order to confirm the findings of this ecological analysis.
These cluster areas may be appropriate to evaluate pancreatic cancer risk factors, and to perform targeted screening and
prevention studies.
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Pancreatic cancer is one of the most common causes of
cancer mortality. The American Cancer Society esti-
mated that 43,140 persons in the US would be diagnosed
with pancreatic cancer in 2010, and that 94% of the
patients will die from this highly lethal malignancy [1].
Each year 250,000 people worldwide will die of pancre-
atic cancer [2]. Late diagnosis, lack of therapeutic op-
tions, and the aggressive biological nature of pancreatic
cancer cells play major roles in the traditionally poor
prognosis of pancreatic cancer [3]. Although efforts are
being made to understand the initiation and progression
of this cancer and to identify the factors that confer its* Correspondence: wliu@med.miami.edu
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reproduction in any medium, provided the orparticular aggressiveness, the exact environmental and/
or genetic events underlying the development of this
malignancy remain undiscovered.
Although the etiology of pancreatic cancer is largely
unknown after decades of intensive research, smoking is
one of the few factors consistently associated with pan-
creatic cancer risk. It is estimated that smoking accounts
for 20-25% of all pancreatic tumors. People who use
smokeless (spit or chew) tobacco are also more likely to
develop pancreatic cancer. Previous studies have demon-
strated that smokers have a 1.5-3 times increased risk of
developing pancreatic cancer [4-15]. In an addition to
cigarette smoking, consistent evidence of a positive asso-
ciation has been found between family history and pan-
creatic cancer. With the exception of tobacco smoking
and family history, other risk factors for pancreatic can-
cer have not been well-established.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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rence in populations highly exposed to arsenic occupation-
ally, medicinally, or through exposure to contaminated
drinking water [16,17]. Many of the more recent studies
linking arsenic exposure to these cancer outcomes were
conducted in countries outside of the US, such as Scandi-
navian countries [18,19], Taiwan [20-23], Argentina [24]
and Chile [25]. In this latter study, odds of lung cancer
increased in a dose–response fashion with increasing
exposure to arsenic-contaminated drinking water. Rela-
tive to those with low exposure (mean urinary arsenic
level < 9 ug/l), the odds of lung cancer in the highest ex-
posure category (mean urinary concentration = 825 ug/l)
was 7.1 (3.4-14.8) [25]. Significant elevated risk was ob-
served at mean urinary concentrations as low as 126.1 ug/l
(OR = 3.4; 95% CI = 1.8-6.5). In the study conducted in
Argentina, ingested arsenic was associated with a signifi-
cant increased risk of bladder cancer in smokers but not
among nonsmokers (2.17; 1.02-4.63) [24].
More recent US-based studies have examined associa-
tions between arsenic exposure and bladder, skin, and
lung cancers [26-28]. In a study of arsenic-contaminated
drinking water wells in New Hampshire, there was an
elevated but non-significant odds ratio for bladder can-
cer for the uppermost category of arsenic exposure as
determined by toenail analysis among ever smokers
(2.17; 0.92-5.11); there was no evidence of an increased
cancer risk in never smokers irrespective of arsenic expo-
sure levels [26]. In another analysis conducted in this
state, those in the most extreme exposure category (>97th
percentile) had an age and gender adjusted odds ratio for
squamous cell carcinoma of 2.07 (0.92- 4.66) [27]. Finally,
a case–control study drawn from residents of New Hamp-
shire and Vermont found that arsenic exposure was
associated with risk of small-cell and squamous-cell car-
cinoma of the lung (2.75; 1.0- 7.57) among those with toe-
nail arsenic concentration > 0.114 ug/g versus < 0.05 ug/g
[28]. In Florida, clusters of bladder cancer were found
among those who live in close proximity to known
arsenic-contaminated drinking water wells [29].
In contrast to the research on bladder, skin, and lung
cancers, there appears to be no consistent association
between arsenic exposure and pancreatic cancer [30]
and virtually no recent research on this topic in the US.
However, as indicated above arsenic may have a role as a
co-carcinogen when paired with other carcinogens such
as smoking [24,26]. Over the past five years, pancreatic
cancer has been one of the few invasive malignancies
that have been rising in Florida 2002–2006, and the
mortality rate of this fatal cancer has not changed
(http://www.cdc.gov/cancer/npcr/). In this study, we sought
to ascertain if there were any pancreatic cancer clusters in
Florida, and to identify socio-demographic and behavioral
correlates associated with these clusters. Controlling forthese factors, we also explored if pancreatic cancer cluster
membership was associated with proximity to identified
arsenic-contaminated drinking water wells.
Methods
Overview
Florida residents diagnosed with pancreatic cancer be-
tween 1998 and 2002 were identified by the State of
Florida incidence cancer registry, the Florida Cancer
Data System (FCDS). The International Classification of
Diseases (ICD) – Oncology, 3rd edition was used to
code primary site and morphology (site code C25.0
through C25.9 and all morphologies). Residence at the
time of diagnosis was recorded and geocoded for spatial
analysis at the census block-group level. The block group
was chosen because it is the smallest geographic unit for
which US census data are available. It allows more precise
socioeconomic status assignment than the census tract
or zip code. This study was approved by the University of
Miami and the Florida Department of Health Institutional
Review Boards.
Cancer registry data
The Florida Cancer Data System (http://fcds.med.miami.
edu/) (FCDS) has collected incident cancer data since
1981. FCDS is part of the National Program of Cancer
Registries (NPCR), which is administered by the Centers
for Disease Control (CDC). Cancer incidence data are
submitted to the FCDS from all hospitals, laboratories,
ambulatory surgical centers, and radiation therapy centers
in Florida. There are approximately 115,000 newly diag-
nosed cancer cases per year among Florida’s 17.5 million
residents in 67 counties. At present, the FCDS database
contains more than 2.7 million cancer incidence records.
Health data
Aggregated patient data were the numerator data; the
aggregated 2000 census population (multiplied by five to
reflect the number of incident years and also stratified
by gender and age group) was the denominator data
for the spatial analyses. We utilized spatial analysis to
identify the clusters of block groups with higher than
expected pancreatic cancer incidence, and logistic re-
gression analysis to model the probability of pancreatic
cancer cases falling within and outside of these geographic
clusters at the time of diagnosis as a function of socioeco-
nomic status, reported tobacco use, and proximity to
known arsenic-contaminated wells.
The dependent variable was the block group assign-
ment of having an excess incidence of pancreatic cancer
versus an expected or lower pancreatic cancer incidence
using cluster detection software (as described below).
The independent variables were patient (i.e. FCDS de-
rived data) and area-based (census derived) measures, as
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nosis and arsenic-contaminated wells as documented by
the Florida Department of Health; race/ethnic categories;
census-derived poverty status at the block-group level;
and census-derived county-level urban/rural residence.
Smoking status provided by patient self-report was
obtained from the medical record at the time of pancreatic
cancer diagnosis in the FCDS record.Arsenic contamination data
The detailed procedure of collecting arsenic contamin-
ation data has been described previously [29]. Arsenic
data were provided by the Florida Department of Health
Drinking Water Toxics Program, a non-regulatory pro-
gram responsible for coordinating groundwater sampling
for chemical contamination of private drinking water
supplies throughout Florida. A total of 5,707 arsenic
samples were collected from December 2000 to May
2008 by the Florida Department of Health, representing
more than 5,000 individual privately owned wells that
were tested for arsenic. During that period, 551 samples
were detected with 0.010 ppm (10 ppb) or greater arsenic
levels in private well water. For study purposes, we consid-
ered 10 ppb as the threshold since during this period the
United States Environmental Protection Agency (EPA)
changed the standard for arsenic from 50 to 10 ppb in
public water systems. Although private wells are consid-
ered non-regulatory, the Florida Department of Health
recognizes the EPA standard as the maximum contain-
ment level in drinking water.
The distance between patient residences and contami-
nated drinking water wells was calculated in miles using
the ArcGIS™, version 9.0 buffering feature. For all block
groups in the respective buffers, the patient record was
annotated with the number of miles. Results were cate-
gorized into greater than three miles, between greater
than one and three miles or less, and less than or equal
to 1 mile from a known arsenic-contaminated drinking
water well.Spatial and statistical analysis
ArcGIS, version 9.0 was the geographic information system
used for this analysis to view, analyze, calculate distance
and relate data from a spatial (geographic) perspective.
SaTScan™, version 5.0, was used to identify block groups in
Florida with excess pancreatic cancer [31,32]. FCDS pan-
creatic cancer data were aggregated at the block group
level by gender and age group, and served as SaTScan
numerators. Using Monte Carlo techniques, SaTScan
assigned relative risk probabilities to defined block groups
to detect both the location of clusters and evaluate their
statistical significance. Race and the standard age (18 years)
groups were used as covariates in this analysis.Under the null hypothesis, the incidence of pancreatic
cancer follows a Poisson distribution, and the probability
of a case being diagnosed in a particular location is pro-
portional to the covariate-adjusted population in the lo-
cation. For hypothesis testing, the SaTScan program
generated 999 random replications of the data set under
the null hypothesis. The test statistic was calculated for
each random replication as well as for the real data set.
When the latter was among the 5% highest, the test was
significant at the 0.05 level [32]. Multiple testing of clus-
ter locations and sizes was adjusted in analyses of the
spatial scan statistic [33,34].
Multivariable logistic regression with SPSSW, version
11.0.1, was performed to assess potential predictor vari-
ables across groups. In these models, the dependent
variable was a patient with pancreatic cancer living in
a neighborhood (“block groups”) with a higher than
expected pancreatic cancer incidence (a “cluster”) versus
not being diagnosed in a cluster. Gender and age were
not part of the multivariate logistic regression models
because they were already incorporated as covariates in
the SaTScan analysis to identify areas of higher than
expected incidence. Reported odds ratios (OR) and 95%
confidence intervals (CI) are adjusted for all model covari-
ates (e.g. distance to a contaminated well, race/ethnicity,
urban/rural location, and tobacco use). Figure 1 shows the
steps of these analyses.
Results
From 1998 through 2002 in Florida, 11,405 patients 13
to 104 years old (median age 73.0) were diagnosed with
pancreatic cancer (Table 1). The majority of cases were
white, non-Hispanic (81.3%). Most of the diagnosed
cases lived more than three miles from known arsenic-
contaminated wells (90.6%), although nearly 3% of cases
were living less than one mile from known arsenic-
contaminated wells at the time of diagnosis.
Spatial analysis results
During the study period, patients with pancreatic cancer
lived in 1753 of the 9112 block groups in Florida. There
were 16 clusters identified with a higher than expected
pancreatic cancer rate. This represented 2619 patients or
23.0% of all the pancreatic cancer cases (Table 1). Figure 2
depicts these clusters and the locations of arsenic-
contaminated wells in Florida. Clusters tended to be
located on the Eastern and Western coasts below the
“Panhandle” region of the state.
Multivariable logistic regression analyses
After adjustment for sociodemographic and smoking
status, pancreatic cancer cases were more likely to be in
areas of a higher than expected incidence when living
near a drinking water well known to contain arsenic
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Figure 1 Steps of Data Analyses.
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contaminated wells were significantly more likely to be di-
agnosed within a cluster of pancreatic cancers relative to
cases living more than 3 miles from known sites (OR = 2.1;
95% CI = 1.9- 2.4); on the other hand, compared to casesTable 1 Characteristics of Florida pancreatic cancer cases,
1998-2002
Number of pancreatic cases (%)
Total number of cases 11,405
Proximity to arsenic- contaminated wells
>3 miles 10330 (90.6%)
1-3 miles 746 (6.5%)
<= 1 mile 329 (2.9%)
Poverty status
Non Poverty 8,572 (75.2%)
Poverty 1,951 (17.1%)
Unspecified 882 (7.7%)
Race/ethnicity
Non-Hispanic white 9271 (81.3%)
African-American 956 (8.4%)
Hispanic 1043 (9.1%)
Unspecified 135 (1.2%)
Gender
Male 5718 (50.2%)
Female 5681 (49.8%)
Unspecified 6 (0.0%)
Tobacco use
Never 3880 (34.0%)
Current smoker 2671 (23.4%)
Former smoker 1791 (15.7%)
Other/Unknown 3063 (26.9%)
Pancreatic cancer cases
Clustered* 2,581 (22.6%)
Non-Clustered 8,824 (77.4%)
*Based on 16 identified clusters.living more than 3 miles from known sites, there was no
increased risk for those living within 1–3 miles of a known
site (1.0; 0.8- 1.2).
Poverty status was not associated with being diagnosed
outside versus inside a pancreatic cancer cluster. Self-
reported tobacco use at diagnosis was slightly, but sig-
nificantly associated with being diagnosed within versus
outside a pancreatic cancer cluster compared with non-
smokers (1.1; 1.0-1.2). There was also a slightly reduced
risk of diagnosis within a pancreatic cancer cluster among
former smokers relative to non-smokers (0.9; 0.8-1.0).
Compared to Caucasians, there was a significantly increased
risk of diagnosis within versus outside of a pancreatic
cancer cluster among African- Americans (1.6; 1.3-1.8),
with an opposite pattern noted for Hispanics relative to
Caucasians (0.7; 0.6- 0.8).Discussion
In our study, we identified 16 specific areas in Florida
where pancreatic cancer cases were significantly higher
than expected. These areas tended to be in urban as op-
posed to rural communities. Furthermore, we found an
association between relatively close proximity to arsenic-
contaminated drinking water wells and clusters of pan-
creatic cancer. Specifically, we found that living within
1 mile of the known arsenic-contaminated drinking water
well might be a threshold distance for an increased risk of
being diagnosed within a cluster. Community poverty sta-
tus was unrelated to cancer cluster membership, but we
did find that African-American Floridians diagnosed with
pancreatic cancer were more likely to be diagnosed within
versus outside of these 16 cancer clusters.
As discussed above, the etiology of pancreatic cancer
is largely unknown after decades of studying this highly
fatal disease. Smoking is one of the few factors found
consistently associated with pancreatic cancer. Differ-
ences in exposure to tobacco smoke across communities
in Florida could partially explain the presence of pancre-
atic cancer clusters, although we were unable to fully
Figure 2 Pancreas Cancer Clusters overlaid with Arsenic Contaminated Wells in Florida 1998–2002: green circles represent arsenic
contaminated wells and red areas represent higher than expected pancreatic cancer clusters.
Table 2 Multivariable-adjusted correlates of living within
versus outside of one of 16 pancreatic cancer clusters at
the time of diagnosis, Florida 1998–2002 (n = 11,405)
Odds ratios (95% CI)
Proximity to arsenic
contaminated well water
>3 miles 1.0
1-3 miles 1.0 (0.8, 1.2)
<= 1 mile 2.1 (1.9, 2.4)
Social economic status
Non poverty 1.0
Poverty 1.1 (0.9, 1.2)
Tobacco use
Never 1.0
Current smoker 1.1 (1.0, 1.2)
Former smoker 0.9 (0.8, 1.0)
Other/unknown 1.1 (1.0, 1.3)
Race/ethnicity
Non-Hispanic white 1.0
African-American 1.6 (1.3, 1.8)
Hispanic 0.7 (0.6, 0.8)
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on smoking status collected at the time of cancer
diagnosis.
In animal models, low concentrations of arsenic expo-
sures alone do not cause cancers. However, the synergis-
tic effects of arsenic and other carcinogens (such as
smoking and ultraviolet irradiation) are suggested to en-
hance the tumorigenicity [35]. Drinking water arsenic
exposure has been associated with increased bladder
cancer susceptibility. The findings of an increased blad-
der cancer risk among smokers but not among non-
smokers by Steinmaus et al. [24], and Karagas et al. [26],
suggest that the ingestion of low to moderate arsenic
levels may affect bladder cancer incidence, and that
cigarette smoking may act as a co-carcinogen as a DNA
damaging agent. These findings of synergistic effects of
arsenic and other carcinogens (such as smoking) in blad-
der cancer risk may indicate a similar mechanism for
the development of pancreatic cancer.
The biologic effects of arsenic exposure on cancer risk
remains largely unknown. The carcinogenic mechanisms
of arsenic-induced cancers might be through blocking
DNA repair, stimulating angiogenesis, altering DNA
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duction of aneuploidy, and/or blocking apoptosis [35,36].
Additional pathways suggested include: endocrine disrup-
tion, suppression of hormone regulation and hormone me-
diated gene transcription, alteration of cell cycle kinetics,
and alterations in cellular proliferative response that might
play roles in association with carcinogenesis [37]. Recent
evidence further supports the hypothesis that sources of
DNA damage may interact with arsenic to induce tumori-
genesis. For example, arsenic gene-environment interac-
tions have been identified in several studies [38-40].
While most of these studies have studied other cancers
instead of pancreatic cancer, and have identified impor-
tant adverse health effects associated with relatively
high-dose arsenic exposure, results cannot be extrapolated
to US populations which are typically exposed to lower
levels of arsenic exposure. Additionally, precise measure-
ment of exposure is critical to assessing risk in popula-
tions consuming relatively trace amounts of arsenic.
Other factors may also add uncertainties to the results.
For example, not all arsenic exposure studies take expo-
sure to other carcinogens into account (e.g., cigarette
smoking). Another possible limitation is the utilization of
US Environmental Protection Agency (EPA)’s models to
evaluate pancreatic cancer risk, which may underestimate
personal cancer risks for arsenic [41].
Study limitations
The population data were extrapolated for the 5-year
study period by multiplying the single 2000 census year
population by 5 to estimate the denominator data for
spatial analysis which could magnify any inaccuracies in
the data. Smoking status was abstracted from the med-
ical record at the time of cancer diagnosis, which may
be inaccurate. Furthermore, over one fourth of patients
(26.9%) did not report their smoking status. Therefore,
misclassification of this important risk factor is likely
present.
The results of the study may also be influenced by the
completeness and quality of the geocoded data. For this
study, approximately 5% of the pancreatic cases were ex-
cluded from the analysis because their reported residen-
tial address at diagnosis could not be geocoded. Two
percent of the cases were included in the analysis, but
were geocoded to the centroid of the zip code based on
a PO Box address. These cases may not have lived in the
same zip code where their PO Box is located at time of
diagnosis. The ungeocodeable cases were slightly older
(mean age of 72 versus 71) and had a greater percentage
of cases reported at time of death instead of at diagnosis
(13% versus 10%). Conversely, the cases geocoded based
on PO Box were younger (mean age of 68 versus 71)
and less likely to be reported to the cancer registry at
time of death (1% versus 10%).Private non-regulatory drinking water well testing for
arsenic and other chemicals in Florida is not universal.
Samples are usually collected by county health depart-
ments in response to citizen complaints or suspicion
of potential contamination by an anthropogenic source
(e.g., previous agricultural land use). This nonsystematic
ad hoc sampling approach may not accurately identify or
capture where actual concentrations of arsenic may be
in the soil and water. Furthermore, we only had access
to the patient residence at diagnosis and had no infor-
mation on prior residence history in patients with
pancreatic cancer, which is important, given the 15 to
30-year pancreatic cancer latency. The other limitation
of the study pertains to the accuracy of exposure assess-
ment since arsenic levels in the well water may not reflect
individual exposure. While we cannot accurately ascertain
individual well water exposure, in Florida there are more
than 1.5 million private wells from which approximately
20% of the population receives water (http://www.doh.
state.fl.us/environment/water/privatewells.html). If arsenic
is in the soil and air, then arsenic could be dissolved
from the arsenic-bearing soil and air into the ground
water (particularly given the heavy rainfall experienced in
Florida). Therefore, well water may serve as a proxy for
environmental arsenic contamination in the soil and air.
Despite these limitations, we believe that our study
represents the first step in identifying communities that
may benefit from further investigation. Most of previous
studies in literature were done in other countries, with
much higher exposure sources. Our criteria for exposure
was likely much lower in our study. Our study suggests
that these ‘lower’ exposure levels may be important. The
combined and possibly synergistic effects of arsenics
and other carcinogens such as smoking and ultraviolet
irradiation may enhance the tumorigenicity [35]. Factors
which could account for our ability to detect these low-
level exposures could be the completeness of cancer case
registry in Florida, the accuracy of the census-derived
denominator data, the geocoded cases, and the sensitiv-
ity of the SatScan program.
Conclusions
Arsenic exposure in drinking water has been associated
with increased bladder and lung cancer susceptibility.
Epidemiologic and experimental data suggest a co-
carcinogenic effect of arsenic with exposure to DNA
damaging agents, such as cigarette smoke. The findings
of an increased bladder cancer risk among smokers, but
not among nonsmokers by Steinmaus et al. [24] and
Karagas et al. [26] suggest further investigations of ar-
senic, and its interaction with smoking in the develop-
ment of cancers. However, as the current report is an
ecological analysis subject to numerous potential biases
it is important to note that future case–control studies
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on pancreatic cancer risk, and its interactions with other
co-carcinogens such as smoking in the development of
pancreatic cancer.
Future studies to extrapolate cancer risks incorporating
the genetic, environmental factors, and their interactive
relationship to understand the etiology of pancreatic can-
cer, and to identify high-risk populations for primary pre-
vention of this deadly disease will be an important
endeavor to contribute to reduce the burden of the disease
and to promote public health.
There is a public health and clinical imperative to iden-
tify the etiology of pancreatic cancer including environ-
mental factors, and to establish foundations for further
developing effective and targeted pancreatic cancer pre-
vention programs. The present analysis identified multiple
areas of pancreatic cancer clustering within Florida. Fur-
thermore, we identified pancreatic cancer clusters that
had an increased likelihood of being located near known
arsenic-contaminated wells. If these results are confirmed
using more robust study designs, the targeted public
awareness campaigns are needed in these high risk com-
munities in order to educate residents on ways to reduce
environmental and non-environmental exposures to can-
cer causing agents, especially the need to reduce commu-
nity smoking rates.
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